AbbVie reported a strong third quarter with adjusted diluted earnings per share (EPS) of $3.82, more than doubling from the previous year, driven by a 10.3% increase in net revenues to $17.4 billion. Key growth came from its immunology and neuroscience portfolios, with products like Skyrizi and Rinvoq showing significant revenue gains. The company completed the acquisition of Apogee Therapeutics, enhancing its immunology pipeline, and raised its full-year 2026 adjusted EPS guidance. Additionally, AbbVie announced a 5.2% increase in its quarterly dividend, reflecting confidence in its financial outlook and commitment to shareholder returns.
AbbVie shares are trading slightly down by 0.68% at USD 289.00 on Pluang, showing a stable position near its 52-week high of USD 290.97. The stock maintains strong investor interest with 100% buy orders and a dividend yield of 2.38%. These figures are current as of Oct 30, 2026, 19:01 WIB.
AbbVie overcame the loss of exclusivity for its blockbuster drug Humira by successfully growing sales of new drugs Skyrizi and Rinvoq, alongside strategic acquisitions like Allergan. Over the past decade, a $1,000 investment in AbbVie grew to $7,464,...
Four NYSE-listed dividend stocks—UPS, AbbVie, Chevron, and Realty Income—are highlighted for their reliable dividends supported by strong cash flow and long histories of payouts. UPS offers a high yield of about 6.24% with improving dividend coverage...
AbbVie Inc. is trading at all-time highs with a market cap over $500 billion, supported by robust 2026 guidance. The company's Q3 earnings are expected to outperform, mainly due to strong sales from immunology drugs Skyrizi and Rinvoq, projected to g...
AbbVie has submitted a Biologics License Application to the FDA for etentamig, a second-generation bispecific antibody T-cell engager for relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, etentamig demonstrated significant improv...
AbbVie will report its Q3 2026 earnings before market open on October 30, with shares up 28.55% year to date. Options pricing suggests a roughly 5% price move around the release, indicating high expectations. The company recently trimmed its full-yea...
